NCT03237481已完成3 期
A Phase 3, Randomized, Double Blind, Saline Placebo and Active Controlled, Multicenter Study of HTX 011 Via Local Administration for Postoperative Analgesia and Decreased Opioid Use Following Unilateral Open Inguinal Herniorrhaphy
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 418
- 试验地点
- 24
- 主要终点
- Mean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Pain Intensity Scores With Activity (NRS-A) Through 72 Hours Postsurgery (AUC0-72), Compared With Saline Placebo.
研究概览
简要总结
This is a Phase 3, randomized, double-blind, saline placebo- and active-controlled, multicenter study to evaluate the analgesic efficacy and safety of HTX 011 administered via local administration into the surgical site in subjects undergoing unilateral open inguinal herniorrhaphy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Is scheduled to undergo a unilateral open inguinal herniorrhaphy with mesh under general anesthesia.
- •Has an American Society of Anesthesiologists Physical Status of I, II, or III.
- •Female subjects are eligible only if not pregnant, not lactating, not planning to become pregnant during the study, sterile; or using acceptable contraceptives.
排除标准
- •Had any prior inguinal hernia repair.
- •Has a planned concurrent surgical procedure.
- •Has other pre existing concurrent acute or chronic painful physical/restrictive condition expected to require analgesic treatment in the postoperative period for pain.
- •Has a contraindication or a known or suspected history of hypersensitivity or clinically significant idiosyncratic reaction to required study medications.
- •Has known or suspected daily use of opioids for 7 or more consecutive days within the previous 6 months.
- •Has taken NSAIDs within 10 days prior to the scheduled surgery.
- •Has taken opioids within 24 hours prior to the scheduled surgery (3 days for long-acting).
- •Has been administered bupivacaine within 5 days prior to the scheduled surgery.
- •Has initiated treatment with medications within 1 month prior to study drug administration that can impact pain control.
- •Has been administered systemic steroids within 5 half-lives or 10 days prior to administration of study drug.
- •Has a medical condition such that, in the opinion of the Investigator, participating in the study would pose a health risk to the subject or confound the postoperative assessments.
- •Has a known history of Hepatitis B, human immunodeficiency virus (HIV), or active Hepatitis C.
- •Has uncontrolled anxiety, psychiatric, or neurological disorder that, in the opinion of the Investigator, might interfere with study assessments.
- •Had a malignancy in the last year, with the exception of nonmetastatic basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix.
- •Has a known or suspected history of drug abuse, a positive drug screen on the day of surgery, or a recent history of alcohol abuse. Note: Subjects with a positive drug screen who are taking an allowed, prescribed medication that is known to result in a positive drug test (eg, amphetamine and dextroamphetamine for attention deficit/hyperactivity disorder) may be eligible for participation in the study. Subjects taking medical marijuana are not allowed to participate in the study.
- •Received an investigational product or device in a clinical trial within 30 days or within 5 elimination half lives.
- •Has undergone 3 or more surgeries within 12 months.
- •Has a body mass index (BMI) >39 kg/m2.
研究组 & 干预措施
Treatment Group 1: HTX-011
Experimental
HTX 011 (bupivacaine/meloxicam)
干预措施: HTX-011 (Drug)
Treatment Group 1: HTX-011
Experimental
HTX 011 (bupivacaine/meloxicam)
干预措施: Luer-lock applicator (Device)
Treatment Group 1: HTX-011
Experimental
HTX 011 (bupivacaine/meloxicam)
干预措施: Vial access device (Device)
Treatment Group 2: Bupivacaine HCI
Active Comparator
Bupivacaine HCl
干预措施: Bupivacaine HCl (Drug)
Treatment Group 3: Saline Placebo
Placebo Comparator
Saline placebo
干预措施: Saline placebo (Drug)
Treatment Group 3: Saline Placebo
Placebo Comparator
Saline placebo
干预措施: Luer-lock applicator (Device)
结局指标
主要结局
Mean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Pain Intensity Scores With Activity (NRS-A) Through 72 Hours Postsurgery (AUC0-72), Compared With Saline Placebo.
时间窗: 72 hours
Pain intensity is assessed using an 11-point NRS (0-10) where 0 represents "no pain" and 10 represents "worst pain imaginable" (using windowed worst observation carried forward to adjust for opioid rescue medication use). The theoretical range of AUC0-72 is 0-720. The prescribed activity for NRS-A is sitting up from a resting position.
次要结局
- Mean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Pain Intensity Scores With Activity (NRS-A) Through 72 Hours Postsurgery (AUC0-72), Compared With Bupivacaine HCl.(72 hours)
- Mean Total Postoperative Opioid Consumption (in Morphine Equivalents) for HTX 011 Compared With Saline Placebo.(72 hours)
- Percetange of Subjects Who Are Opioid-free for HTX-011 Compared With Bupivacaine HCl.(72 hours)
- Mean Total Postoperative Opioid Consumption (in Morphine Equivalents) for HTX 011 Compared With Bupivacaine HCl.(72 hours)
研究者
研究点 (24)
Loading locations...
相似试验
已完成
3 期
Bunionectomy Study for Postoperative Analgesia (EPOCH 1)Postoperative PainNCT03295721Heron Therapeutics412
终止
3 期
Flecainide Acetate Inhalation Solution for Cardioversion of Recent-Onset, Symptomatic Atrial FibrillationParoxysmal Atrial FibrillationNCT05039359InCarda Therapeutics, Inc.54
撤回
3 期
Phase 3, Randomized, Safety, Lot Consistency and Clinical Benefit Study of Recombinant Botulinum Vaccine A/BBotulismNCT01940315DynPort Vaccine Company LLC, A GDIT Company
已完成
3 期
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole PR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-DopaParkinson DiseaseNCT01154166GlaxoSmithKline347
已完成
3 期
A Study of Retreatment With Rituximab in Patients With Rheumatoid Arthritis Receiving Background MethotrexateRheumatoid ArthritisNCT00266227Genentech, Inc.559